⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for adult acute basophilic leukemia

Every month we try and update this database with for adult acute basophilic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531NCT01407757
Leukemia
DNA analysis
gene expression...
laboratory biom...
pharmacogenomic...
- 29 YearsChildren's Oncology Group
Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid LeukemiaNCT00089050
Leukemia
cyclosporine
gemtuzumab ozog...
60 Years - Fred Hutchinson Cancer Center
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaNCT01627041
Acute Myeloid L...
Adult Acute Bas...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Alkylating Agen...
Secondary Acute...
Cytarabine
Daunorubicin Hy...
Decitabine
Laboratory Biom...
Pharmacological...
18 Years - 65 YearsNational Cancer Institute (NCI)
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaNCT00101231
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Blastic Phase C...
Recurrent Adult...
Recurrent Adult...
Relapsing Chron...
alvocidib
1 Year - National Cancer Institute (NCI)
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaNCT00093483
Leukemia
filgrastim
arsenic trioxid...
cytarabine
idarubicin
18 Years - 59 YearsRoswell Park Cancer Institute
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid LeukemiaNCT01159301
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Blastic Phase C...
Recurrent Adult...
Unspecified Adu...
entinostat
sorafenib tosyl...
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous LeukemiaNCT00003758
Leukemia
cytarabine
idarubicin
allogeneic bone...
autologous bone...
peripheral bloo...
15 Years - 60 YearsNational Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaNCT00217646
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Pro...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Blastic Phase
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Secondary Acute...
Secondary Myelo...
Sorafenib Tosyl...
18 Years - National Cancer Institute (NCI)
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive ChemotherapyNCT01235572
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Previously Trea...
Recurrent Adult...
standard follow...
medical chart r...
quality-of-life...
18 Years - 75 YearsFred Hutchinson Cancer Center
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep RNCT00534469
Leukemia
aldesleukin
filgrastim
busulfan
cytarabine
etoposide
idarubicin
autologous hema...
bone marrow tra...
peripheral bloo...
total-body irra...
16 Years - 60 YearsCity of Hope Medical Center
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaNCT00027872
Acute Myeloid L...
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Ery...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Cellular Diagno...
Untreated Adult...
tipifarnib
laboratory biom...
65 Years - National Cancer Institute (NCI)
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid LeukemiaNCT00354276
Leukemia
cytarabine
laromustine
60 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesNCT00454480
Leukemia
Myelodysplastic...
alemtuzumab
arsenic trioxid...
azacitidine
busulfan
clofarabine
cytarabine
daunorubicin hy...
fludarabine pho...
gemtuzumab ozog...
melphalan
tipifarnib
DNA methylation...
cytogenetic ana...
gene expression...
mutation analys...
diagnostic labo...
immunologic tec...
allogeneic hema...
nonmyeloablativ...
- National Cancer Institute (NCI)
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaNCT00651261
Leukemia
cytarabine
daunorubicin
midostaurin
placebo
dexamethasone a...
18 Years - 59 YearsAlliance for Clinical Trials in Oncology
Biomarkers in Blood Samples From Patients With Acute Myeloid LeukemiaNCT01385150
Leukemia
mutation analys...
protein analysi...
laboratory biom...
liquid chromato...
mass spectromet...
17 Years - 60 YearsEastern Cooperative Oncology Group
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaNCT00027872
Acute Myeloid L...
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Ery...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Cellular Diagno...
Untreated Adult...
tipifarnib
laboratory biom...
65 Years - National Cancer Institute (NCI)
Lenalidomide in Treating Older Patients With Acute Myeloid LeukemiaNCT00352365
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Secondary Acute...
Untreated Adult...
lenalidomide
60 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaNCT00006363
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Ery...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Myelo...
de Novo Myelody...
Untreated Adult...
Untreated Child...
cytarabine
daunorubicin hy...
etoposide
valspodar
filgrastim
busulfan
autologous hema...
peripheral bloo...
aldesleukin
clinical observ...
pharmacological...
15 Years - 59 YearsNational Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaNCT00217646
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Pro...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Blastic Phase
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Secondary Acute...
Secondary Myelo...
Sorafenib Tosyl...
18 Years - National Cancer Institute (NCI)
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep RNCT00534469
Leukemia
aldesleukin
filgrastim
busulfan
cytarabine
etoposide
idarubicin
autologous hema...
bone marrow tra...
peripheral bloo...
total-body irra...
16 Years - 60 YearsCity of Hope Medical Center
Cilengitide in Treating Patients With Acute Myeloid LeukemiaNCT00089388
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
cilengitide
50 Years - National Cancer Institute (NCI)
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive ChemotherapyNCT01235572
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Previously Trea...
Recurrent Adult...
standard follow...
medical chart r...
quality-of-life...
18 Years - 75 YearsFred Hutchinson Cancer Center
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing ChemotherapyNCT02071901
Acute Myeloid L...
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Secondary Acute...
eltrombopag ola...
60 Years - Case Comprehensive Cancer Center
Multidrug Resistance Genes in Patients With Acute Myeloid LeukemiaNCT00898456
Leukemia
gene expression...
molecular genet...
polymorphism an...
protein express...
diagnostic labo...
15 Years - Alliance for Clinical Trials in Oncology
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast PhaseNCT00383474
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Blastic Phase
Recurrent Adult...
Recurrent Adult...
Recurrent Disea...
Untreated Adult...
Untreated Adult...
Bortezomib
Laboratory Biom...
Tipifarnib
18 Years - National Cancer Institute (NCI)
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaNCT00131989
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Recurrent Adult...
Recurrent Adult...
sorafenib tosyl...
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AMLNCT00085709
Leukemia
gemtuzumab ozog...
observation
Cytosine arabin...
Daunomycin
18 Years - 60 YearsSWOG Cancer Research Network
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received ChemotherapyNCT00509093
Leukemia
imatinib mesyla...
gene expression...
mutation analys...
polymerase chai...
flow cytometry
biopsy
18 Years - Case Comprehensive Cancer Center
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaNCT00651261
Leukemia
cytarabine
daunorubicin
midostaurin
placebo
dexamethasone a...
18 Years - 59 YearsAlliance for Clinical Trials in Oncology
S0106B Studying Bone Marrow Samples From Women With Acute Myeloid LeukemiaNCT01575535
Leukemia
gene expression...
flow cytometry
fluorescence ac...
laboratory biom...
medical chart r...
18 Years - SWOG Cancer Research Network
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaNCT00407966
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Secondary Acute...
Untreated Adult...
alvocidib
cytarabine
mitoxantrone hy...
18 Years - National Cancer Institute (NCI)
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaNCT00096122
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Childhood Myelo...
Chronic Myelomo...
de Novo Myelody...
Refractory Anem...
Refractory Anem...
Secondary Acute...
Secondary Myelo...
Untreated Adult...
cytarabine
idarubicin
tipifarnib
15 Years - 70 YearsNational Cancer Institute (NCI)
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaNCT00096122
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Childhood Myelo...
Chronic Myelomo...
de Novo Myelody...
Refractory Anem...
Refractory Anem...
Secondary Acute...
Secondary Myelo...
Untreated Adult...
cytarabine
idarubicin
tipifarnib
15 Years - 70 YearsNational Cancer Institute (NCI)
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT01550185
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Recurrent Adult...
eltrombopag ola...
standard follow...
18 Years - Roswell Park Cancer Institute
Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid LeukemiaNCT00775593
Leukemia
clofarabine
temsirolimus
60 Years - Gruppo Italiano Malattie EMatologiche dell'Adulto
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaNCT00027872
Acute Myeloid L...
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Ery...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Cellular Diagno...
Untreated Adult...
tipifarnib
laboratory biom...
65 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid LeukemiaNCT00372593
Leukemia
asparaginase
cytarabine
daunorubicin hy...
etoposide
gemtuzumab ozog...
mitoxantrone hy...
- 29 YearsChildren's Oncology Group
S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based ChemotherapyNCT01360125
Leukemia
proteomic profi...
flow cytometry
laboratory biom...
18 Years - 60 YearsSWOG Cancer Research Network
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid LeukemiaNCT00112554
Leukemia
cytarabine
laromustine
placebo
18 Years - National Cancer Institute (NCI)
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing ChemotherapyNCT02071901
Acute Myeloid L...
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Secondary Acute...
eltrombopag ola...
60 Years - Case Comprehensive Cancer Center
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing ChemotherapyNCT02071901
Acute Myeloid L...
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Secondary Acute...
eltrombopag ola...
60 Years - Case Comprehensive Cancer Center
Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaNCT01154439
Leukemia
cytarabine
etoposide
everolimus
idarubicin
mitoxantrone hy...
61 Years - 75 YearsGruppo Italiano Malattie EMatologiche dell'Adulto
Biomarkers in Blood Samples From Patients With Acute Myeloid LeukemiaNCT01385150
Leukemia
mutation analys...
protein analysi...
laboratory biom...
liquid chromato...
mass spectromet...
17 Years - 60 YearsEastern Cooperative Oncology Group
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaNCT00027872
Acute Myeloid L...
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Ery...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Cellular Diagno...
Untreated Adult...
tipifarnib
laboratory biom...
65 Years - National Cancer Institute (NCI)
Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care TreatmentNCT01421862
Leukemia
DNA methylation...
RNA analysis
gene expression...
microarray anal...
mutation analys...
nucleic acid se...
laboratory biom...
18 Years - 65 YearsNational Cancer Institute (NCI)
S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based ChemotherapyNCT01360125
Leukemia
proteomic profi...
flow cytometry
laboratory biom...
18 Years - 60 YearsSWOG Cancer Research Network
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT01550185
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Recurrent Adult...
eltrombopag ola...
standard follow...
18 Years - Roswell Park Cancer Institute
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous LeukemiaNCT00003758
Leukemia
cytarabine
idarubicin
allogeneic bone...
autologous bone...
peripheral bloo...
15 Years - 60 YearsNational Cancer Institute (NCI)
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaNCT00006363
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Ery...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Myelo...
de Novo Myelody...
Untreated Adult...
Untreated Child...
cytarabine
daunorubicin hy...
etoposide
valspodar
filgrastim
busulfan
autologous hema...
peripheral bloo...
aldesleukin
clinical observ...
pharmacological...
15 Years - 59 YearsNational Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaNCT00217646
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Pro...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Blastic Phase
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Secondary Acute...
Secondary Myelo...
Sorafenib Tosyl...
18 Years - National Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaNCT00217646
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Pro...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Blastic Phase
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Secondary Acute...
Secondary Myelo...
Sorafenib Tosyl...
18 Years - National Cancer Institute (NCI)
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid LeukemiaNCT00112554
Leukemia
cytarabine
laromustine
placebo
18 Years - National Cancer Institute (NCI)
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaNCT00131989
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Recurrent Adult...
Recurrent Adult...
sorafenib tosyl...
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesNCT00098423
Accelerated Pha...
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Blastic Phase C...
Chronic Myelomo...
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Refractory Anem...
Relapsing Chron...
Secondary Acute...
Secondary Myelo...
tanespimycin
cytarabine
18 Years - National Cancer Institute (NCI)
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaNCT00101153
Leukemia
cytarabine
daunorubicin hy...
tipifarnib
56 Years - University Health Network, Toronto
XK469R in Treating Patients With Refractory Hematologic CancerNCT00095797
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Blastic Phase C...
Chronic Myelomo...
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Refractory Anem...
Refractory Anem...
Refractory Chro...
Relapsing Chron...
Secondary Myelo...
Stage III Chron...
Stage IV Chroni...
Untreated Adult...
R(+)XK469
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaNCT00091234
Leukemia
gemtuzumab ozog...
61 Years - European Organisation for Research and Treatment of Cancer - EORTC
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous LeukemiaNCT00258271
Leukemia
filgrastim
cladribine
cytarabine
imatinib mesyla...
18 Years - University of Rochester
S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based ChemotherapyNCT01360125
Leukemia
proteomic profi...
flow cytometry
laboratory biom...
18 Years - 60 YearsSWOG Cancer Research Network
A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic LeukemiaNCT01656031
Leukemia
clofarabine
cytarabine
18 Years - 120 YearsWake Forest University Health Sciences
Genetics Study of Tissue Collected From Patients With Acute Myeloid LeukemiaNCT00898092
Leukemia
microarray anal...
molecular genet...
mutation analys...
polymerase chai...
reverse transcr...
diagnostic labo...
15 Years - 59 YearsAlliance for Clinical Trials in Oncology
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid LeukemiaNCT01159301
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Blastic Phase C...
Recurrent Adult...
Unspecified Adu...
entinostat
sorafenib tosyl...
pharmacological...
laboratory biom...
18 Years - National Cancer Institute (NCI)
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaNCT00844441
Leukemia
Myelodysplastic...
medical chart r...
questionnaire a...
quality-of-life...
18 Years - 60 YearsFred Hutchinson Cancer Center
S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaNCT00023777
Leukemia
filgrastim
sargramostim
cytarabine
daunorubicin hy...
56 Years - SWOG Cancer Research Network
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous LeukemiaNCT00258271
Leukemia
filgrastim
cladribine
cytarabine
imatinib mesyla...
18 Years - University of Rochester
Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaNCT01154439
Leukemia
cytarabine
etoposide
everolimus
idarubicin
mitoxantrone hy...
61 Years - 75 YearsGruppo Italiano Malattie EMatologiche dell'Adulto
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaNCT00091234
Leukemia
gemtuzumab ozog...
61 Years - European Organisation for Research and Treatment of Cancer - EORTC
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: